NextCure, Inc. (NXTC)

NMS – Real vaqt narxi. Valyuta: USD

6.92

+0.19 (2.82%)

Bozor ochiq: Aug 12, 2026, 11:38 AM EDT

6.76

+0.03 (0.48%)

Oldingi bozordan keyin: Aug 11, 2026, 7:45 PM EDT

10.08.2026

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029 SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the "Company"), a privately-held biotechnology company advancing oral therapies for IL-23 driven inflammatory diseases, today announced a $500 million private placement (the "Private Placement") from a syndicate of leading healthcare investors. The Private Placement is in addition to the previously announced $320 million concurrent private investment, and the combined proceeds will support the continued development of Avere's lead program, AVR-001, a once-weekly oral IL-23 receptor antagonist.

Videolar

No Data

There is no data to display

Press-relizlar

10.08.2026

NextCure, Inc. (NXTC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NextCure, Inc. (NXTC)

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videolar

No Data

Press-relizlar

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videolar

No Data

Press-relizlar

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Search stocks

NextCure, Inc. (NXTC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

NextCure, Inc. (NXTC)

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videolar

No Data

Press-relizlar

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001

Videolar

No Data

Press-relizlar

Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001